

REFERENCES

1. Levey AS, Coresh J. Chronic kidney disease. *Lancet*. 2011; 379: 165-80.
2. Menon V, Sarnak MJ. The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. *Am J Kidney Dis*. 2005; 45: 223-32.
3. Utaka S, Avesani CM, Draibe SA, Kamimura MA, Andreoni S, Cuppari L. Inflammation is associated with increased energy expenditure in patients with chronic kidney disease. *Am J Clin Nutr*. 2005; 82: 801-5.
4. Stames HF, Warren RS, Jeevanandam M, Gabrilove JL, Larchian W, Oettgen HF, et al. Tumor necrosis factor and the acute metabolic response to tissue injury in man. *J Clin Invest*. 1988; 82: 1321-5.
5. Bistrian BR. Role of the systemic inflammatory response syndrome in the development of protein-calorie malnutrition in ESRD. *Am J Kidney Dis*. 1998; 32: 113-7.
6. Biolo G, Toigo G, Ciocchi B, Situlin R, Iscra F, Gullo A, et al. Metabolic response to injury and sepsis: changes in protein metabolism. *Nutrition*. 1997; 13: 52-7.
7. Borah MF, Schoenfeld PY, Gotch FA, Sargent JA, Wolfson M, Humphreys MH. Nitrogen balance during intermittent dialysis therapy of uremia. *Kidney Int*. 1978; 14: 491-500.
8. Wolfson M, Jones MR, Kopple JD. Amino acid losses during hemodialysis with infusion of amino acids and glucose. *Kidney Int*. 1982; 21: 500-6.

9. Monteon FJ, Laidlaw SA, Shaib JK, Kopple JD. Energy expenditure in patients with chronic renal failure. *Kidney Int.* 1986; 30: 741-7.
10. Ikizler TA, Wingard RL, Sun M, Harvell J, Parker RA, Hakim RM. Increased energy expenditure in hemodialysis patients. *J Am Soc. Nephrol.* 1996; 7: 2646-53.
11. Ikizler TA, Pupim LB, Brouillette JR, Levenhagen DK, Farmer K, Hakim RM, et al. Hemodialysis stimulates muscle and whole body protein loss and alters substrate oxidation. *Am J Physiol Endocrinol Metab.* 2002; 282: 107-16.
12. Katzarski KS. Monitoring of blood volume during haemodialysis treatment of acute renal and multiple organ failures. *Nephrol Dial Transplant.* 1996; 11: 20-3.
13. Zawada ET, Daugirdas JT, Blake PG, Ing TS, editors. *Handbook of dialysis.* 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2001: 3-11.
14. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Wyck DV, Bunnapradist S, Horwich TB, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. *Circulation.* 2009; 119: 671-9.
15. Maher JF, Schreiner GE. Hazards and complications of dialysis. *New Engl J Med.* 1965; 273: 370-7.
16. Ingsathit A, Thakkinstian A. Prevalence and risk factors of chronic kidney disease in the Thai adult population: Thai SEEK study. *Nephrol Dial Transplant.* 2010; 25: 1567-75.
17. Haynes R, Winerls C. Chronic kidney disease. *Basic Science.* 2010; 28: 525-9.
18. Nissenson AR, Fine RN. *Dialysis therapy.* 3rd ed. Hanley&Belfus Inc; 2002: 128-78.

19. Levy J, Morgan J, Brown E. Oxford handbook of dialysis. Britain G, editor. Oxford University Press Inc; 2001.
20. Kallenbach J, Gutch C, Stoner M, Corea A. Review of hemodialysis for nurses and dialysis personnel. 2nd ed. USA: Elsevier Mosby; 2005.
21. Alvestrand A. Carbohydrate and insulin metabolism in renal failure. *Kidney Int Suppl.* 1997; 62: 48-52.
22. Rigalleau V, Gin H. Carbohydrate metabolism in uremia. *Curr Opin Clin Nutr Metab Care.* 2005; 8: 463-9.
23. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. *N Engl J Med.* 1987; 317: 350-7.
24. Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto M, Kishimoto H, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. *J Am Soc Nephrol.* 2001; 12: 2117-24.
25. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. *J Am Soc Nephrol.* 2002; 13: 1894-900.
26. Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepor M, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. *Circulation.* 2001; 104: 342-5.
27. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. *Am J Kidney Dis.* 1993; 21: 573-92.

28. Guarnieri G, Fonda M, Situlin R, Vasile A, Toigo G, Cattin L. Effects of L-carnitine supplementation in the dialysate on serum lipoprotein composition of hemodialysis patients. *Contrib Nephrol.* 1992; 98: 36-43.
29. Cibulka R, Racek J, Vesela E. The importance of L-carnitine in patients with chronic renal failure treated with hemodialysis (in Czech). *Vnitr Lek.* 2005; 51: 1108-13.
30. Cibulka R, Racek J. Metabolic disorders in patients with chronic kidney failure. *Physiol Res.* 2007; 56: 697-705.
31. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high density lipoprotein associated paraoxonase. *Atherosclerosis.* 1993; 104: 129-35.
32. Brautbar N. Skeletal myopathy in uremia: abnormal energy metabolism. *Kidney Int (Suppl).* 1983; 16: 81-6.
33. Floyd M, Ayyar DR, Barwick DD, Hudgson P, Weightman D. Myopathy in chronic renal failure. *Q J Med.* 1974; 43: 509-24.
34. Moore GE, Parsons DB, Stray-Gundersen J, Painter PL, Brinker KR, Mitchell JH. Uremic myopathy limits aerobic capacity in hemodialysis patients. *Am J Kidney Dis.* 1993; 22: 277-87.
35. Davenport A. The effect of treatment with recombinant human erythropoietin on skeletal muscle function in patients with end-stage renal failure treated with regular hospital hemodialysis. *Am J Kidney Dis.* 1993; 22: 685-90.
36. Clyne N, Esbjornsson M, Jansson E, Jogestrand T, Lins L, Pehrsson SK. Effects of renal failure on skeletal muscle. *Nephron.* 1993; 63: 395-99.

37. Diesel W, Emms M, Knight BK, Noakes TD, Swanepoel CR, Smit R, et al. Morphologic features of the myopathy associated with chronic renal failure. *Am J Kidney Dis.* 1993; 22: 677-84.
38. Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. *Am J Kidney Dis.* 2005; 45: 978-93.
39. Kovacica V, Roguljicb L, Kovacicc V. Metabolic acidosis of chronically hemodialyzed patients. *Am J Nephrol.* 2003; 23: 158-64.
40. Ravussin E, Lillioja S, Anderson TE, Christin L, Bogardus C. Determinants of 24-hour energy expenditure in man. *J Clin Invest.* 1986; 78: 1568-78.
41. Krishnan AV, Kiernan MC. Neurological complications of chronic kidney disease. *Nat Rev Neurol.* 2009; 5: 542-51.
42. Henrich WL. *Principles and Practice of Dialysis therapy.* 4th ed. MACP. 2009: 101-668.
43. Vilar E, Frarrington K. Hemodialysis. *CRF.* 2011; 39: 429-33.
44. 2004 USRDSU. Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004.
45. Nissenson A, Fine R. *Dialysis therapy.* 2nd ed. Philadelphia: Hanley & Belfus; 1993.
46. Himmelfarb J, Sayegh MH. Chronic kidney disease, Dialysis, and Transplantation Companion to Brenner&Rector's *The Kidney*; 2009: 62-299.
47. Painter P. End-Stage Renal Disease. In: Ehrman J, Gordon P, Visich P, Keteyian S, editors. *Clinical exercise physiology.* USA: Human Kinetics; 2003: 185-200.

48. Moore GE, Parsons DB, Stray-Gundersen J, Painter PL, Brinker KR, Mitchell JH. Uremic myopathy limits aerobic capacity in hemodialysis patients. *Am J Kidney Dis.* 1993; 22: 277-87.
49. Moore GE, Brinker KR, Stray-Gundersen J, Mitchell JH. Determinants of VO_2 peak in patients with end-stage renal disease: on and off dialysis. *Med Sci Sports Exerc.* 1993; 25: 18-23.
50. Painter P, Messer-Rehak D, Hanson P, Zimmerman SW, Glass NR. Exercise capacity in hemodialysis, CAPD, and renal transplant patients. *Nephron.* 1986; 42: 47-51.
51. Kouidi E, Albani M, Natsis K, Megalopoulos A, Gigis P, Guiba-Tziampiri O, et al. The effects of exercise training on muscle atrophy in haemodialysis patients. *Nephrol Dial Transplant.* 1998; 13: 685-99.
52. Painter P, Carlson L, Carey S, Paul SM, Myll J. Physical functioning and health-related quality-of-life changes with exercise training in hemodialysis patients. *Am J Kidney Dis.* 2000; 35: 482-92.
53. Peter FM, editors. National Research Council Recommended Dietary Allowances 10 ed. Washington, D.C: 1989.
54. Keys A, Taylor HL, Grande F. Basal metabolism and age of adult man. *Metabolism.* 1973; 22: 579-87.
55. Roberts SB, Young VR, Fuss P, Heyman MB, Fiatarone M, Dallal GE, et al. What are the dietary energy needs of elderly adults? *Int J Obes Relat Metab Disord.* 1992; 16: 969-76.

56. Elliot DL, Goldberg L, Kuehl KS, Bennett WM. Sustained depression of the resting metabolic rate after massive weight loss. *Am J Clin Nutr.* 1989; 49: 93-6.
57. Tzankoff SP, Norris AH. Effect of muscle mass decrease on age-related BMR changes. *J Appl Physiol.* 1977; 43: 1001-6.
58. Chapman IM. The anorexia of aging. *Clin Geriatr Med.* 2007; 23: 735-56.
59. Goran MI, Poehlman ET. Total energy expenditure and energy requirements in healthy elderly persons. *Metabolism;* 1992: 744-53.
60. Ravussin E, Burnand B, Schutz Y, Jequier E. Energy expenditure before and during energy restriction in obese patients. *Am J Clin Nutr.* 1985; 41: 753-59.
61. Leibel RL, Hirsch J. Diminished energy requirements in reduced-obese patients. *Metabolism.* 1984; 33: 164-70.
62. Amatruda JM, Statt MC, Welle SL. Total and resting energy expenditure in obese women reduced to ideal body weight. *J Clin Invest.* 1993; 92: 1236-42.
63. Ferraro R, Lillioja S, Fontvieille AM, Rising R, Bogardus C, Ravussin E. Lower sedentary metabolic rate in women compared with men. *J Clin Invest.* 1992; 90: 780-4.
64. Toth MJ, Gottlieb SS, Fisher ML, Poehlman ET. Daily energy requirements in heart failure patients. *Metabolism.* 1997; 46: 1294-8.
65. Creutzberg EC, Schols AM, Bothmer-Quaedvlieg FC, Wouters EF. Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. *Eur J Clin Nutr.* 1998; 52: 396-401.

66. Muller MJ, Lautz HU, Plogmann B, Bürger M, Korber J, Schmidt FW. Energy expenditure and substrate oxidation in patients with cirrhosis: the impact of cause, clinical staging and nutritional state. *Hepatology*. 1992; 15: 782-94.
67. Silva P. Renal fuel utilization, energy requirements, and function. *Kidney Int*. 1987; 32: 9-14.
68. Om P, Hohenegger M. Energy metabolism in acute uremic rats. *Nephron*. 1980; 25: 249-53.
69. Kurnik B, Weisberg LS, Kurnik PB. Renal and systemic oxygen consumption in patients with normal and abnormal renal function. *J Am Soc Nephrol*. 1992; 2: 1617-26.
70. Consolazio CF, Johnson RE, Pecora. *Physiological Measurements of Metabolic Functions in Man*. New York: McGraw Hill Book Company; 1963.
71. Kopple JD, Monteob FJ, Shaib JK. Effect of energy intake on nitrogen metabolism in nondialyzed patients with chronic renal failure. *Kidney Int*. 1986; 29: 734-42.
72. Weir JVB. New methods for calculating metabolic rate with special reference to protein metabolism. *J Physiol Lond*. 1949; 109: 1-9.
73. Warburton D, Nicol CW, Bredin S. Health benefits of physical activity: the evidence. *CMAJ*. 2006; 174: 801-9.
74. Haskell WL, Lee IM, Pate RR, Powell KE, Blair SN, Franklin BA, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. *Med Sci Sports Exerc*. 2007; 39: 1423-34.

75. Johansen KL, Chertow GM, Ng AV, Mulligan K, Carey S, Schoenfeld PY, et al. Physical activity levels in patients on hemodialysis and healthy sedentary controls. *Kidney Int.* 2000; 57: 2564-70.
76. Ohare AM, Tawney K, Bacchetti P, Johansen KL. Decreased survival among sedentary patients undergoing dialysis: results from the dialysis morbidity and mortality study wave 2. *Am J Kidney Dis.* 2003; 41: 447-54.
77. Painter P. Physical functioning in end-stage renal disease patients: update 2005. *Hemodial Int.* 2005; 9: 218-35.
78. Johansen KL, Shubert T, Doyle J, Soher B, Sakkas GK, Kent-Braun JA. Muscle atrophy in patients receiving hemodialysis: effects on muscle strength, muscle quality, and physical function. *Kidney Int.* 2003; 63: 291-7.
79. McIntyre CW, Selby NM, Sigrist M, Pearce LE, Mercer TH, Naish PF. Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease. *Nephrol Dial Transplant.* 2006; 21: 2210-6.
80. Charkoudian N, Joyner MJ, Sokolnicki LA, Johnson CP, Eisenach JH, Dietz NM, et al. Vascular adrenergic responsiveness is inversely related to tonic activity of sympathetic vasoconstrictor nerves in humans. *J Physiol.* 2006; 572: 821-7.
81. Charkoudian N, Martin EA, Dinunno FA, Eisenach JH, Dietz NM, Joyner MJ. Influence of increased central venous pressure on baroreflex control of sympathetic activity in humans. *Am J Physiol Heart Circ Physiol.* 2004; 287: 1658-62.

82. Charkoudian N, Joyner MJ, Johnson CP, Eisenach JH, Dietz NM, Wallin BG. Balance between cardiac output and sympathetic nerve activity in resting humans: role in arterial pressure regulation. *J Physiol*. 2005; 568: 315-21.
83. Wiinberg N, Høegholm A, Christensen HR, Bang LE, Mikkelsen KL, Nielsen PE, et al. 24-h ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. *Am J Hypertens*. 1995; 8: 978-86.
84. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. *Hypertension*. 1995; 25: 305-13.
85. Fu Q, Witkowski S, Okazaki K, Levine BD. Effects of gender and hypovolemia on sympathetic neural responses to orthostatic stress. *Am J Physiol Regul Integr Comp Physiol*. 2005; 289: 109-16.
86. Roos N, Wahab MA, Chamnan C, Thilsted SH. The role of fish in food-based strategies to combat vitamin A and mineral deficiencies in developing countries. *J Nutr*. 2007; 137: 1106-9.
87. Kneale BJ, Chowienczyk PJ, Brett SE, Coltart DJ, Ritter JM. Gender differences in sensitivity to adrenergic agonists of forearm resistance vasculature. *J Am Coll Cardiol*. 2000; 36: 1233-8.
88. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO. Acute vascular effects of estrogen in postmenopausal women. *Circulation*. 1994; 90: 786-91.

89. Volterrani M, Rosano G, Coats A, Beale C, Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. *Am J Med.* 1995; 99: 119-22.
90. Jones PP, Shapiro LF, Keisling GA, Jordan J, Shannon JR, Quaipe RA, et al. Altered autonomic support of arterial blood pressure with age in healthy men. *Circulation.* 2001; 104: 2424-9.
91. Ferrer M, Meyer M, Osol G. Estrogen replacement increases beta-adrenoceptor-mediated relaxation of rat mesenteric arteries. *J Vasc Res.* 1996; 33: 124-31.
92. Lakatta EG. Do hypertension and aging have a similar effect on the myocardium? *Circulation.* 1987; 75: 69-77.
93. Brandfonbrener M, Dow-ne ML, Shock NW. Changes in cardiac output with age. *Circulation.* 1955; 12: 557-66.
94. Blumenthal JA, Emey CF, Madden DJ, George LK, Coleman RE, Riddle MW, et al. Cardiovascular and behavioral effect of aerobic exercise training in health older men and women. *Journal of Gerontology.* 1989; 44: 147-57.
95. Senneff MJ, Geltman EM, Bergmann SR. Noninvasive delineation of the effects of moderate aging on myocardial perfusion. *J Nucl Med.* 1991; 32: 2037-42.
96. Brandfonbrener M, Landowne M, Shoc NW. Changes in Cardiac Output with Age. *Circulation.* 1955; 12: 557-66.
97. Silaruks S, Sirivongs D, Chunlertrith D. Left ventricular hypertrophy and clinical outcome in CAPD patients. *Peritoneal Dialysis International.* 2000; 20: 461-6.


98. Kalantar-Zadeh K, Abbott KC, Kronenberg F, Anker SD, Horwich TB, Fonarow GC. Epidemiology of dialysis patients and heart failure patients. *Seminars in Nephrology*. 2006; 26: 118-33.
99. Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC. Nutritional and anti-inflammatory interventions in chronic heart failure. *Am J Cardiol*. 2008; 101: 89-103.
100. Horwich TB, Kalantar-Zadeh K, MacLellan RW, Fonarow GC. Albumin levels predict survival in patients with systolic heart failure. *Am Heart J*. 2008; 155: 883-9.
101. Kalantar-Zadeh K, Horwich TB, Oreopoulos A, Kovesdy CP, Younessi H, Anker SD, et al. Risk factor paradox in wasting diseases. *Curr Opin Clin Nutr Metab Care*. 2007; 10: 433-42.
102. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. *J Am Coll Cardiol*. 2004; 43: 1439-44.
103. Abraham PA, Opsahl JA, Keshaviah PR, Collins AJ, Whalen JJ, Asinger RW, et al. Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. *Am J Kidney Dis*. 1990; 16: 438-46.
104. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of heamoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. *Nephrol Dial Transplant*. 2000; 15: 1425-30.
105. Cannella G, Guerra UP, Sandrini M, Gaggiotti M, Traverso GB, Rolla D, et al. Changes in partition of extracellular fluid volumes in anemic dialyzed uremic

- patients after partial correction of the anemia with recombinant human erythropoietin treatment. *Clin Nephrol.* 1993; 40: 164-7.
106. Foley RN, Herzog CA, Collins A. Declining incidence and mortality of cardiovascular diseases in older end-stage renal disease patients in the United States. *J Am Soc Nephrol.* 2002; 13: 1987-97.
107. Cotter G, Felker GM, Adams KF, Milo-Cotter O, Oconnor CM. The pathophysiology of acute heart failure is it all about fluid accumulation? *Am Heart J.* 2008; 155: 9-18.
108. Jessup M, Brozena S. Heart failure. *N Engl J Med.* 2003; 348: 2007-8.
109. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. *N Engl J Med* 1999; 341: 577-85.
110. Perez AV, Anker SD, Dietz R, Rauchhaus M. Are diuretics overused in the treatment of chronic heart failure? *Nature Reviews Cardiology.* 2008; 5: 238-9.
111. Haehling SV, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. *J Am Coll Cardiol.* 2007; 50: 1973-80.
112. Haynes GR, Moreau X, Rousseau JM, Thiranos JC, Dubè L. Cardiac output with a new bioimpedance monitor: comparison with thermodilution methods. *Anesthesiology.* 2006; 105: 470.
113. Tan KH, Lai FO, Hwang NC. Measurement of cardiac output using Physio Flow® with different positions of electrode placement. *Singapore Med J.* 2006; 47: 967.

114. Hampers CL, Skillman JJ, Lyons JH, Olen JE, Merrill JP. A hemodynamic evaluation of bilateral nephrectomy and hemodialysis in hypertensive man. *Circulation*. 1967; 35: 272-88.
115. Perret C, Mueller G. Validation of a new portable ergospirometric device (Oxycon Mobile®) during exercise. *Int J Sports Med*. 2006; 27: 363-7.
116. Instructions for use oxycon mobile. Cardinal health germany 234 GmbH. Hoechberg, Germany 2008. 781023-52.
117. Agarwal R, Lewis RR. Prediction of hypertension in chronic hemodialysis patients. *Kidney International*. 2001; 60: 1982-9.
118. เกียรติพงษ์ สว่าง. Initiation of renal replacement therapy (RRT). *Practical hemodialysis*; 2548.
119. Mara NB. Anemia in patients with chronic kidney disease. *diabetes spectrum*. 2008; 21: 12-9.
120. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Laboratory reference values. *N Engl J Med*. 2004; 351: 1548-63.
121. Cargill WH, Hickam JB. The oxygen consumption of the normal and the diseased human kidney. *J Clin Invest*. 1949; 28: 526-32.
122. Goedecke JH, Gibson ASC, Grobler L, Collins M, Noakes TD, Lambert EV. Determinants of the variability in respiratory exchange ratio at rest and during exercise in trained athletes. *Am J Physiol Endocrinol Metab*. 2000; 279: 1325-34.

123. Gadegbeku CA, Shrayyef MZ, Ullian ME. Hemodynamic effects of chronic hemodialysis therapy assessed by pulse waveform analysis. *Am J Hypertens.* 2003; 16: 814-7.
124. Goss JE, Alfrey AC, Vojel JHK, Holmes JH. Hemodynamic changes during hemodialysis. *Amer. Soc. Artif. Int;* 1967: 68-74.
125. Chaignon M, Chen WT, Tarazi RC, Bravo EL, Nakamoto S. Effect of hemodialysis on blood volume distribution and cardiac output. *Hypertension.* 1981; 3: 327-32.
126. Vertes V, Cangiano JL, Berman LB, Gould A. Hypertension in end-stage renal disease. *N Engl J Med.* 1969; 280: 978-81.
127. Blumberg A, Nelp WD, Hegstrom RM, Scripner B. Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction. *Lancet.* 1967; 2: 69-73.
128. Goldberg AP, Tindira C, Harter HR. Coronary risk in patients with end-stage renal disease: Interaction of hypertension with hyperlipidemia. *J Cardiovasc Pharmacol;* 1982: 257-61.
129. Guyton AC, Granger HJ, Coleman TG. Autoregulation of the total systemic circulation and its relation to cardiac output and arterial pressure. *Circ Res.* 1971; 28: 93-7.
130. Levin NW, Zhu F, Keen M. Interdialytic weight gain and dry weight. *Blood Purif.* 2001; 19: 217-21.

131. Dasselaar JJ, Jong PE, Huisman RM, Franssen FM. Effect of high and low ultrafiltration volume during hemodialysis on relative blood volume. *ASAIO Journal*. 2006; 52: 169-173.



ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่
Copyright© by Chiang Mai University
All rights reserved